Fri, Dec 26, 2014, 3:28 PM EST - U.S. Markets close in 32 mins.


% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • dickunger2 dickunger2 Oct 24, 2012 3:51 PM Flag

    More bad news for HALO

    This is a rough week for Halozyme Therapeutics (NASDAQ:HALO). The company’s rating falls to D from the previous week’s C. Halozyme Therapeutics is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The stock receives F’s in Earnings Growth, Earnings Momentum, Equity, and Sales Growth. Wall Street appears to agree with the stock downgrade, with share prices dropping 29.5% over the past month. To get an in-depth look at HALO, get Portfolio Grader’s complete analysis of HALO stock.

9.58+0.24(+2.57%)3:27 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.